[HTML][HTML] miRNA-embedded shRNAs for lineage-specific BCL11A knockdown and hemoglobin F induction

S Guda, C Brendel, R Renella, P Du, DE Bauer… - Molecular Therapy, 2015 - cell.com
S Guda, C Brendel, R Renella, P Du, DE Bauer, MC Canver, JK Grenier, AW Grimson
Molecular Therapy, 2015cell.com
RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA
polymerase (pol) III promoters has been widely exploited to modulate gene expression in a
variety of mammalian cell types. For certain applications, such as lineage-specific
knockdown, embedding targeting sequences into pol II-driven microRNA (miRNA)
architecture is required. Here, using the potential therapeutic target BCL11A, we
demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also …
RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA polymerase (pol) III promoters has been widely exploited to modulate gene expression in a variety of mammalian cell types. For certain applications, such as lineage-specific knockdown, embedding targeting sequences into pol II-driven microRNA (miRNA) architecture is required. Here, using the potential therapeutic target BCL11A, we demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also increased cytotoxcity in comparison to pol II-driven miRNA adapted shRNAs (shRNAmiR) in multiple hematopoietic cell lines. We show that the two expression systems yield mature guide strand sequences that differ by a 4 bp shift. This results in alternate seed sequences and consequently influences the efficacy of target gene knockdown. Incorporating a corresponding 4 bp shift into the guide strand of shRNAmiRs resulted in improved knockdown efficiency of BCL11A. This was associated with a significant de-repression of the hemoglobin target of BCL11A, human γ-globin or the murine homolog Hbb-y. Our results suggest the requirement for optimization of shRNA sequences upon incorporation into a miRNA backbone. These findings have important implications in future design of shRNAmiRs for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.
cell.com